Hello, Guest!

Moderna Secures $472M BARDA Contract Modification for COVID-19 Vaccine Dev’t

Moderna has been awarded a potential $472M contract modification by the Biomedical Advanced Research and Development Authority to expand late-stage clinical trials of a messenger RNA-based vaccine candidate for the novel coronavirus.

BARDA’s additional funding commitment increases the potential value of the initial contract to $955M, the company said Sunday.

Under the modification, BARDA pledged funds to support Phase 3 tests of Moderna’s mRNA-1273 vaccine  including a study to be conducted with 30K participants.

The biotechnology firm will perform the participant-based trials with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases’ COVID-19 Prevention Trials Network.

“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” said Moderna CEO Stephane Bancel.

The company aims to deliver 500M to 1B doses of the potential COVID-19 vaccine starting next year as part of the Trump administration’s Operation Warp Speed.

Video of the Day

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles